Mepolizumab intravenous (IV) vs placeboHealth‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 369 participantsHigh
Reslizumab intravenous (IV) vs placeboHealth‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 1652 participantsHigh
Reslizumab subcutaneous (SC) vs placeboHealth‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 464 participantsHigh
Mepolizumab subcutaneous (SC) vs placeboHealth‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 1231 participantsHigh
Benralizumab subcutaneous (SC) vs placeboHealth‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma1 finding from 1 reviewAnti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 2791 participantsHigh